NCT02058407View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Food Effect of Single or Repeat Doses of GSK2793660 in Healthy Subjects

PHASE1TerminatedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

January 28, 2014

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Bronchiectasis
Interventions
DRUG

GSK2793660 solution

Clear, colourless solution at a unit dose strength of 0.1 mg/mL, in a glass bottle

DRUG

GSK2793660 capsule

Size zero swedish orange capsule at a unit dose of 3 mg, 10 mg, 20 mg and 50 mg

DRUG

Placebo solution

Matching placebo to GSK2793660 solution

DRUG

Placebo capsule

Matching placebo to GSK2793660 capsule

Trial Locations (1)

NW10 7EW

GSK Investigational Site, London

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY